GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » PS Ratio

CG Oncology (CG Oncology) PS Ratio : 2,725.45 (As of May. 17, 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CG Oncology's share price is $29.98. CG Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.01. Hence, CG Oncology's PS Ratio for today is 2,725.45.

The historical rank and industry rank for CG Oncology's PS Ratio or its related term are showing as below:

CGON' s PS Ratio Range Over the Past 10 Years
Min: 778.44   Med: 977.33   Max: 3727.27
Current: 2464.94

During the past 3 years, CG Oncology's highest PS Ratio was 3727.27. The lowest was 778.44. And the median was 977.33.

CGON's PS Ratio is ranked worse than
98% of 1000 companies
in the Biotechnology industry
Industry Median: 9.155 vs CGON: 2464.94

CG Oncology's Revenue per Sharefor the three months ended in Mar. 2024 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.01.

Warning Sign:

CG Oncology Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of CG Oncology was -7.80% per year.

Back to Basics: PS Ratio


CG Oncology PS Ratio Historical Data

The historical data trend for CG Oncology's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology PS Ratio Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
PS Ratio
- - -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial - - - - 3,990.91

Competitive Comparison of CG Oncology's PS Ratio

For the Biotechnology subindustry, CG Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CG Oncology's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's PS Ratio distribution charts can be found below:

* The bar in red indicates where CG Oncology's PS Ratio falls into.



CG Oncology PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

CG Oncology's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=29.98/0.011
=2,725.45

CG Oncology's Share Price of today is $29.98.
CG Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


CG Oncology  (NAS:CGON) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


CG Oncology PS Ratio Related Terms

Thank you for viewing the detailed overview of CG Oncology's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CG Oncology (CG Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines